- Language: English
- 113 Pages
- Published: August 2013
Global Biosimilars Market 2014-2018
- ID: 2768571
- February 2014
- Region: Global
- 106 pages
The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market.
The report, the Global Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc.
Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd.
Key questions answered in this report:
- What will the market size be in 2016/2018 and what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Biosimilars Market in the US
06.3.1 Market Size and Forecast
06.4 Biosimilars Market in Europe
06.4.1 Market Size and Forecast
06.5 Biosimilars Market in Japan
06.5.1 Market Size and Forecast
06.6 Biosimilars Market in India
06.6.1 Market Size and Forecast
06.7 Biosimilars Market in China
06.7.1 Market Size and Forecast
06.8 Five Forces Analysis
07. Market Segmentation by Application
08. Geographical Segmentation
08.1 Biosimilars Market in the APAC Region
08.1.1 Market Size and Forecast
08.2 Biosimilars Market in the EMEA Region
08.2.1 Market Size and Forecast
08.3 Biosimilars Market in the Americas
08.3.1 Market Size and Forecast
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
16.3 Other Prominent Vendors
16.3.1 Competitive Analysis in the US
16.3.2 Competitive Analysis in Europe
16.3.3 Competitive Analysis in Japan
16.3.4 Competitive Analysis in India
16.3.5 Competitive Analysis in China
17. Patent Expiries
18. Key Vendor Analysis
18.1 Biocon Ltd.
18.1.1 Business Overview
18.1.2 Business Segmentation
18.1.3 Key Information
18.1.4 SWOT Analysis
18.2 Celltrion Inc.
18.2.1 Business Overview
18.2.2 Key Information
18.2.3 SWOT Analysis
18.3 Dr. Reddy's Laboratories Ltd.
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 F. Hoffmann-La Roche Ltd.
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
18.5 Hospira Inc.
18.5.1 Business Overview
18.5.2 Business Segmentation
18.5.3 Key Information
18.5.4 SWOT Analysis
18.6 Intas Pharmaceuticals Ltd.
18.6.1 Business Overview
18.6.2 Key Information
18.6.3 SWOT Analysis
18.7 Mylan Inc.
18.7.1 Business Overview
18.7.2 Business Segmentation
18.7.3 Key Information
18.7.4 SWOT Analysis
18.8 Novartis AG
18.8.1 Business Overview
18.8.2 Business Segmentation
18.8.3 Key Information
18.8.4 SWOT Analysis
18.9 Teva Pharmaceutical Industries Ltd.
18.9.1 Business Overview
18.9.2 Business Segmentation
18.9.3 Key Information
18.9.4 SWOT Analysis
18.11 3SBio Inc.
18.11.1 Business Overview
18.11.2 Key Information
18.11.3 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Biosimilars Market 2013-2018 (US$ million)
Exhibit 3: Biosimilars Market in the US 2013-2018 (US$ million)
Exhibit 4: Biosimilars Market in Europe 2013-2018 (US$ million)
Exhibit 5: Biosimilars Market in Japan 2013-2018 (US$ million)
Exhibit 6: Biosimilars Market in India 2013-2018 (US$ million)
Exhibit 7: Biosimilars Market in China 2013-2018 (US$ million)
Exhibit 8: Global Biosimilars Market Segmentation by Application
Exhibit 9: Global Biosimilars Market by Geographical Segmentation 2013
Exhibit 10: Biosimilars Market in the APAC Region 2013-2018 (US$ million)
Exhibit 11: Biosimilars Market in the EMEA Region 2013-2018 (US$ million)
Exhibit 12: Biosimilars Market in the Americas 2013-2018 (US$ million)
Exhibit 13: Global Biosimilars Market by Geographical Segmentation (US$ million)
Exhibit 14: Global Biosimilars Market by Geographical Segmentation
Exhibit 15: Comparison of YOY Growth Rates among various Geographies in the Global Biosimilars Market
Exhibit 16: Business Segmentation of Biocon Ltd.
Exhibit 17: Business Segmentation of Dr. Reddy's Laboratories Ltd.
Exhibit 18: Business Segmentation of F. Hoffmann-La Roche Ltd.
Exhibit 19: Business Segmentation of Hospira Inc.
Exhibit 20: Business Segmentation of Mylan Inc.
Exhibit 21: Business Segmentation of Novartis AG
Exhibit 22: Business Segmentation of Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from the team said: “The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. ”
According to the report, one of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan.
Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Biocon Ltd.
- Hospira Inc.
- Mylan Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- 3SBio Inc.
- Celltrion Inc.
- Actavis plc
- Amgen Inc.
- AstraZeneca plc
- Baxter International Inc.
- Biogen Idec Inc.
- Bioton S.A.
- Boehringer Ingelheim GmbH
- Cipla Ltd.
- Coherus Biosciences Inc.
- Daiichi Sankyo Co. Ltd.
- Emcure Pharmaceuticals Ltd.
- GE Healthcare Ltd.
- GeneScience Pharmaceuticals Co. Ltd.
- GlaxoSmithKline plc
- JCR Pharmaceuticals Co. Ltd.
- iBio Inc.
- LG Life Sciences Co. Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- Ranbaxy Laboratories Ltd.
- Samsung Biologics Co. Ltd.
- Sanofi S.A.
- and Wockhardt Ltd.